Lichenoid eruptions with interface dermatitis and necrotic subepidermal blister associated with COVID ‐19

Dermatological manifestations associated with COVID‐19: A comprehensive review of the current knowledge

“… 36 Several other lesions have been reported for COVID‐19, some of which cannot be categorized into one of the mentioned groups. Examples include pityriasis rosea‐like rash, 37 Grover's disease‐like eruptions, 23 , 38 acro‐ischemia, 39 malar erythema, and facial edema, 40 palmar erythema, 41 symmetrical drug‐related intertriginous and flexural exanthema (SDRIFE)‐like eruptions, 42 hand‐foot‐mouth‐like diseases, 24 “COVID toes” or pernio‐like eruptions, 43 Dengue‐like rashes, 33 diffuse melanoderma, 44 gangrene, 45 paronychia, 46 sacral and buttocks ulcerations, 47 mottling, 48 lichenoid eruptions, 49 drug reaction with eosinophilia and systemic symptom (DRESS), 50 acute generalized exanthematous pustulosis (AGEP), 51 Raynaud's phenomenon, 52 eruptive cherry angioma, 1 violaceous macules with “porcelain‐like” appearance, 53 IgA vasculitis, 54 leukocytoclastic vasculitis, 55 retiform purpura, eosinophilic panniculitis, 56 and periorbital dyschromia. 57 …”

COVID-19: The experience from Iran

“…Other reported findings were acral vasculitis/vasculopathy ( Figure 4 ); livedoid vasculopathy lesions; vesicular herpetiform lesions ( Figure 5 ); necrotic lesions; Kawasaki-like, disseminated zoster; small vessel vasculitis; pyoderma gangrenosum–like lesions; pityriasis lichenoides et varioliformis acuta–like lesions; oral red macules; and oral aphthous-like lesions and vesicles. 80 , 81 , 82 Severe telogen effluvium was also a common problem for patients after recovery.

Fig.

…”

Rapid Progression of Localized Morphea to Disseminated Plaque-Type Morphea Following COVID-19 Infection

“…Since the emerging of the SARS-CoV-2 pandemic, different COVID-19-associated manifestations have been reported, involving nervous, hematologic, and endocrine systems [ 1 ]. As the largest organ of the body, the skin has not been an exception and is reported to be involved in COVID-19 patients with diverse manifestations, including maculopapular, vesicular, lichenoid, urticarial, vasculitis, and chilblain-like lesions [ 2 , 3 ]. Herein, we report a stable case of localized morphea which progressed rapidly to disseminated morphea following COVID-19 infection.…”